Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 954.54M |
| Revenue (ttm) | 1.52M |
| Net Income (ttm) | -66.74M |
| Shares Out | 44.16M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $20.23 |
| Previous Close | $21.30 |
| Change ($) | -1.07 |
| Change (%) | -5.02% |
| Day's Open | 21.03 |
| Day's Range | 19.85 - 21.30 |
| Day's Volume | 765,668 |
| 52-Week Range | 6.65 - 26.44 |
WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody ...
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...
WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...
Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.
WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...
WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...
WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript
WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.
Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352
Syndax Pharmaceuticals stock tumbled to a month-low Friday after the biotech's breast cancer treatment failed in a Phase 3 test. Syndax says it won't be asking for FDA approval.
WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACR...
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q1 2020 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syndax Pharmaceuticals soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment in leukemia patients. The post...
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.
Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It al... [Read more...]
| Industry Biotechnology | IPO Date Mar 3, 2016 |
| CEO Arlene Morris | Employees 35 |
| Stock Exchange NASDAQ | Ticker Symbol SNDX |
Financial Performance
In 2019, SNDX's revenue was $1.52 million, a change of 0.00% compared to the previous year's $1.52 million. Losses were -$56.05 million, -24.22% less than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is 32.50, which is an increase of 60.65% from the latest price.